| abstract |
The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A 1 -A 6 and R 1 -R 4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer. |